Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG in Pediatric Toxic Shock Syndrome
2018-000102-33Phase 2Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Jan 2018
- Countries
- 1
01
Overview
Phase 2, randomised trial of polyvalent human immunoglobulin in toxic shock syndrome (TSS), Streptococcal toxic shock syndrome (STSS) and staphylococcal toxic shock syndrome (TSS) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Change in organ dysfunction (PELOD-2 score) from admission to day 3. Planned start Jan 2018; status: withdrawn.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
toxic shock syndrome (TSS)Streptococcal toxic shock syndrome (STSS)staphylococcal toxic shock syndrome (TSS)
Beyond the preview
Go deeper on 2018-000102-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000102-33.